Clinical Trial

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Study acronym: FLAMMINGO
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-30.
Status change: Not Yet Recruiting → Recruiting 2025-02-03
Trial Details
NCT Number NCT06668792
Lead Sponsor Biocad
Conditions Relapsed/Refractory Multiple Myeloma
Enrollment 100 participants
Start Date 2024-12-26
Primary Completion 2026-02 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-04